V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryUK FSA Novel Food (Post-Brexit)
Compliance · The complete guide

UK FSA Novel Food (Post-Brexit)

In short

A novel ingredient needs its own Great Britain authorisation under assimilated Regulation (EU) 2015/2283, run by the FSA (England & Wales) and Food Standards Scotland — a pre-2021 EU authorisation does not automatically carry across, and Northern Ireland follows a different track under the Windsor Framework.

3,410 words · ~16 min read
Botanical ingredient in a glass dish beside an authorisation dossier and a UK map outline in a laboratory
Ingredients without a UK consumption history before May 1997 need novel food authorisation. Editorial illustration; not a customer photograph.
On this page
  1. 01What counts as a "novel" food or food ingredient
  2. 02Retained Regulation (EU) 2015/2283 after Brexit
  3. 03Who runs it: FSA, Food Standards Scotland, and the GB split
  4. 04Northern Ireland: a different track under the Windsor Framework
  5. 05The authorisation process and dossier expectations, at a high level
  6. 06The CBD and cannabinoid novel foods episode as a documented example
  7. 07What this means for supplement brands using botanicals or new ingredients
  8. 08Data requirements and the safety assessment, at a high level
On this page · 8 sections
  1. 1What counts as a "novel" food or food ingredient
  2. 2Retained Regulation (EU) 2015/2283 after Brexit
  3. 3Who runs it: FSA, Food Standards Scotland, and the GB split
  4. 4Northern Ireland: a different track under the Windsor Framework
  5. 5The authorisation process and dossier expectations, at a high level
  6. 6The CBD and cannabinoid novel foods episode as a documented example
  7. 7What this means for supplement brands using botanicals or new ingredients
  8. 8Data requirements and the safety assessment, at a high level
AI · Explain it for MY operation

How does UK FSA Novel Food (Post-Brexit) apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What counts as a "novel" food or food ingredient

Under UK law a novel food is any food or food ingredient that was not used for human consumption "to a significant degree" within the United Kingdom or the European Union before 15 May 1997. The FSA's own novel foods guidance states this directly: products without that history of consumption (often shortened to "HoC") are novel, and it gives worked examples — phytosterol and phytostanol spreads marketed as new cholesterol-lowering foods, traditional foods eaten elsewhere in the world but not in the UK/EU before the cut-off (chia seeds, baobab are the FSA's own examples), and foods made using a new production process, such as bread treated with ultraviolet light to raise its vitamin D content. Food Standards Scotland's parallel guidance for Scotland repeats the identical 15 May 1997 cut-off and the same three illustrative categories, confirming the date and definition apply UK-wide in Great Britain, not just to England and Wales.

The 15 May 1997 date is not arbitrary housekeeping — it is the date the original EU novel foods regime, Regulation (EC) No 258/97, came into effect, and every subsequent novel foods regulation (including the 2015 recast that GB now runs under) has kept that same reference date for what counts as "pre-existing" versus "novel" consumption. A food or ingredient only clears the bar if there is a demonstrable, significant degree of consumption as food, by humans, in the UK or EU, before that date — not merely that the raw plant or organism existed, or that some part of it was eaten in some form somewhere.

Four broad categories tend to need a novel food determination in a supplement context: ingredients with no prior food use anywhere (a genuinely new synthetic or fermentation-derived compound); traditional foods from outside the UK/EU with no history of consumption inside it; existing foods subjected to a new production process that changes their composition or structure in a way that affects nutritional value, metabolism, or level of undesirable substances; and extracts, isolates, or concentrates of a plant where the extract itself — not the whole plant or a traditional preparation of it — has no history of consumption, even if the source plant is a long-established food. That last category is exactly how CBD extracts came to be classified as novel, discussed below.

02Retained Regulation (EU) 2015/2283 after Brexit

The substantive EU novel foods law — Regulation (EU) 2015/2283 of 25 November 2015, which itself repealed the original 1997 Regulation — did not disappear when the UK left the EU. It was carried into UK domestic law at the end of the Brexit transition period as "retained EU law," and the FSA's current guidance now refers to it as "assimilated Regulation (EU) 2015/2283" — reflecting the terminology change made across UK statute book by the Retained EU Law (Revocation and Reform) Act 2019, under which most retained EU law was re-labelled "assimilated law" from 1 January 2024. The legal text itself — authorisation routes, safety-assessment requirements, and the register mechanism — carried over largely unchanged into Great Britain; what changed is who runs the process and whose market the resulting authorisation covers.

The FSA's novel foods guidance is explicit that "the placing of novel foods on the market in Great Britain (GB) must be in accordance with the assimilated Regulation (EU) 2015/2283," that there are two authorisation routes — a traditional food notification under Article 14, for a food with a history of safe use in a non-EU country, and a full application under Article 10, for everything else — and that the FSA maintains a Register of novel foods reflecting authorisation status "as determined by the appropriate authority (ministers) in England, Scotland and Wales." Decisions on authorisation are made by the relevant minister in Scotland, England and Wales (with Northern Ireland's Minister of Health kept informed under the separate regime described below).

One consequence of the split is already visible in the FSA's own transitional guidance: it states that EU novel food status decisions made before 1 January 2021 still apply in GB by default, but any EU decision made after that date does not automatically apply — a business relying on a post-2021 EU novel food authorisation for a GB launch needs to check whether the same ingredient also has a GB authorisation, because the two decision streams have diverged since the end of the transition period.

03Who runs it: FSA, Food Standards Scotland, and the GB split

Within Great Britain, two statutory food safety authorities share responsibility for novel foods rather than one. The Food Standards Agency covers England and Wales; Food Standards Scotland (FSS) is a separate body with devolved responsibility for food safety in Scotland and describes itself as "responsible for novel food regulations in Scotland." Both bodies run their own guidance pages that describe the same underlying Regulation (EU) 2015/2283 framework, the same two authorisation routes (traditional food notification and full application), and each maintains language about a shared or mirrored Register of novel foods — FSS's own guidance states that it maintains a register reflecting the novel food authorisation status "as determined by the appropriate authority (ministers) in Scotland, England and Wales" and directs businesses to the FSA website to view the authorisations register in practice.

For a brand, this means an authorisation decision is ultimately a GB-wide ministerial decision (England, Wales and Scotland ministers acting together on the same regulated-product dossier), but day-to-day application handling, validation, and guidance can come from either the FSA or FSS depending on where the applicant is based or which authority they approach — the practical answer is to start from whichever authority's guidance applies to the nation the business operates from, and not assume that engaging only the FSA (or only FSS) covers the full GB authorisation.

04Northern Ireland: a different track under the Windsor Framework

Northern Ireland did not follow Great Britain into the assimilated-law regime for novel foods. GOV.UK's guidance on outcomes of novel food consultations states plainly: "In Northern Ireland, EU Food Law relating to novel foods continues to apply under the current terms of the Protocol on Ireland/Northern Ireland" (the Protocol subsequently operating under the Windsor Framework arrangements), and that businesses seeking to establish novel food status for the Northern Ireland market should refer to EFSA and the EU Novel Food Catalogue rather than the GB register. The Novel Foods Regulations (Northern Ireland) 2017, which implement Regulation (EU) 2015/2283 domestically for Northern Ireland, carry an explicit legislative note recording that they are applied with modifications by the Windsor Framework (Enforcement etc.) Regulations 2023, confirming the EU-law link is current, not a leftover from before the Windsor Framework was agreed.

The practical effect for a supplement brand selling into all four UK nations is that a single UK-wide SKU can face two separate novel food determinations: a GB authorisation (FSA/FSS, under assimilated Regulation 2015/2283) for sale in England, Wales and Scotland, and continued adherence to the EU novel foods regime (via EFSA decisions and the EU Novel Food Catalogue) for sale in Northern Ireland. An ingredient authorised in GB is not automatically authorised for the Northern Ireland market, and vice versa — the two lists can and do diverge, and a brand distributing into Northern Ireland needs to check the EU side of the ingredient's status separately rather than assuming the GB authorisation travels.

Two lists, not one

Do not treat "authorised in the UK" as a single fact. Check the GB register (FSA/FSS) for England, Wales and Scotland sales, and separately check EU novel food status (EFSA, the EU Novel Food Catalogue) for Northern Ireland sales, because the two regimes run on different decision tracks since 1 January 2021.

05The authorisation process and dossier expectations, at a high level

Both routes under assimilated Regulation (EU) 2015/2283 — the Article 14 traditional food notification and the Article 10 full application — sit inside the FSA's wider "regulated products" process, which also covers food additives, food enzymes, flavourings, food contact materials, and several other categories that require pre-market authorisation. The FSA's regulated-products application guidance directs applicants who are unsure whether a product needs authorisation to first check the "placing a regulated product on the market" background guidance, and offers a formal determination route — an Article 4 novel food consultation request — for businesses that believe their product has a sufficient pre-1997 history of consumption and want that confirmed rather than guessed at before committing to a full dossier.

A full Article 10 application is a safety-assessment dossier, not a registration form: it is expected to include a description of the novel food (composition, specification, production process), the proposed conditions of use and anticipated intake, information relevant to safety such as toxicological data, and — where the applicant is relying on it — a history-of-consumption case. For an Article 14 traditional food notification, the dossier is built around demonstrating a documented history of safe food use in a non-EU country for at least 25 years, rather than generating new toxicological data from scratch; this route is only available where that history genuinely exists and can be evidenced, and GOV.UK's novel food consultation outcomes page notes that supporting evidence of history of consumption is assessed under what is now numbered as retained Regulation 2018/456 for the purposes of an Article 4 consultation decision on novel status itself.

Applications go through a validation step before any scientific assessment begins — validation checks that the dossier contains the information required by law to proceed, and the FSA's own CBD products guidance describes this explicitly: "validation requires checking that an application contains all information required by law to allow it to proceed through the authorisation process... If any of this information is missing, the application cannot be legally validated." Only a validated application moves into risk assessment. The guidance available publicly describes this process structurally — what categories of information are expected and what the validation/risk-assessment stages check for — rather than publishing a fixed timetable or any outcome promise for a given dossier, and a brand should not plan a launch date around an assumed processing time.

  • Article 4 consultation request: a formal route to ask the FSA (or FSS, via the same Regulated Products Application Service) to determine novel status itself, for a business that believes it has pre-1997 history-of-consumption evidence.
  • Article 14 traditional food notification: for a food with a documented history of safe consumption in a non-EU country, generally expected to cover at least 25 years of use.
  • Article 10 full application: the general route, built around a safety dossier (composition, production process, proposed use levels, anticipated intake, and relevant toxicological or safety data).
  • Validation: a legal-completeness check of the dossier before any scientific risk assessment starts; an incomplete dossier cannot be legally validated.
  • Ministerial decision and Register entry: the decision is made by the relevant minister(s) in England, Wales and Scotland, and an authorised ingredient's terms of use are then set out in the GB Register of novel foods.

06The CBD and cannabinoid novel foods episode as a documented example

CBD is the clearest public illustration of how the GB novel foods regime actually plays out, because the FSA has published a sustained, dated record of its position. The FSA's cannabidiol (CBD) guidance states that "the novel food status of CBD was confirmed in January 2019," and that this covers CBD extracts, CBD isolates (described as highly purified CBD), CBD synthetic products, and any product to which they are added as an ingredient — all classed as novel foods requiring authorisation before lawful sale in the UK. The same guidance draws a distinction some brands miss: hemp seeds (including hemp seed oil, ground hemp seeds, and partially defatted hemp seeds) and water infusions of hemp leaves (without the flowering and fruiting tops) are treated as non-novel because a history of consumption has been demonstrated for those specific forms — but a product made by selectively extracting CBD from any part of the hemp plant is a CBD extract, and is therefore novel, regardless of which plant part the extraction started from.

To manage an existing market of CBD products that were already on sale without authorisation, the FSA ran an exceptional transitional process: it asked industry to submit novel food applications for CBD products that were already on the market on 13 February 2020, with an application deadline of 31 March 2021, and published a public register — "CBD products linked to novel food applications" — listing products whose application had been validated, or judged to be sufficiently progressing toward validation, as a signal to retailers and enforcement bodies about which products had a credible authorisation route underway. The FSA's own framing was direct: "we are advising that products not on the list should be removed from sale." That list is specific to England and Wales and is maintained separately from the full novel foods Register of actually authorised ingredients.

The CBD guidance page content reviewed for this article also records, as of the version opened, that there are no CBD extracts or isolates that have been granted a full novel food authorisation — products on the linked-applications list have a validated or progressing application, which is a different status from having cleared the full Article 10 safety assessment and reached the Register of authorised novel foods. A brand should check the FSA's current CBD guidance and the linked-applications register directly for the live status of a specific product, rather than relying on a snapshot date, because both pages are updated by the FSA on an ongoing basis and the authorisation landscape for any given cannabinoid product can change.

07What this means for supplement brands using botanicals or new ingredients

The practical risk for a supplement brand is rarely a completely synthetic novel compound — it is far more often an established, traditional-sounding botanical that has been processed into a new form: a concentrated extract, isolate, or fermentation product derived from a plant that itself has a long food history. The CBD case shows exactly this mechanism — hemp as a plant and hemp seed as a food are not novel, but the selectively extracted cannabinoid concentrate made from it is treated as a different, novel material. The same logic applies to other extracts, isolates, and "new process" ingredients: a brand cannot assume an ingredient is clear simply because its source plant or organism is familiar.

Before launching a product containing an unfamiliar botanical extract, a new fermentation-derived ingredient, a novel peptide, or any material produced by an atypical extraction or processing method, a brand should check the current GB Register of novel foods (via FSA or FSS) and, separately for Northern Ireland sales, the EU Novel Food Catalogue, to see whether the specific form of the ingredient already has an authorisation, is excluded as non-novel, or has no determination at all. Where there is genuine uncertainty and the business believes the ingredient (in that specific form) has significant pre-1997 consumption history in the UK or EU, the Article 4 consultation route exists specifically to get that question formally answered before committing resources to an application or a launch.

Where an ingredient has no history-of-consumption case and no existing authorisation, the realistic options are to commission or join a full Article 10 (or Article 14, where a genuine non-EU traditional-use case exists) application, to source a different, already-authorised form of the ingredient, or to reformulate around an ingredient that is not novel. None of these is fast, and the public record for CBD — validation taking place years after the February 2020 market deadline, with authorisations for extracts and isolates still not reached as of the material reviewed for this article — illustrates that novel food authorisation timelines for supplement-relevant ingredients have historically run long, not that any particular timeline should be expected for a different ingredient.

08Data requirements and the safety assessment, at a high level

The safety assessment underlying a novel food authorisation is built around the specific material as proposed for sale — its identity and composition, the production process used to make it, the proposed conditions of use and the resulting anticipated intake across the population expected to consume it, and relevant toxicological and, where applicable, allergenicity or nutritional information. Where a history-of-consumption argument is part of the case (either to avoid novel classification altogether via an Article 4 consultation, or to support an Article 14 traditional food notification), the evidence has to establish consumption of the specific food or ingredient as food, by a definable population, to a significant degree, before 15 May 1997 — general cultural, medicinal, or non-food use of a plant or organism, or consumption of a different part or preparation of it, does not automatically establish history of consumption for the specific novel material a brand wants to sell.

Because the dossier has to be complete before validation can occur, assembling consumption-history evidence, production-process documentation, and any safety data in advance of submission — rather than filing an early application and expecting to add it later — is consistent with how the FSA describes the validation gate operating: an application missing required information cannot be legally validated and therefore cannot progress into risk assessment. None of the publicly available guidance reviewed for this article states a promised outcome, fixed processing time, or minimum data package that is certain to satisfy a given assessment — every dossier is evaluated by the risk assessors on its own evidence, and brands should treat the category-level examples in FSA and FSS guidance as illustrative of the kind of information expected, not as a checklist whose completion assures authorisation.

Because this is a pre-market authorisation regime for the ingredient itself, it sits upstream of, and separately from, the general labelling and compositional rules in the Food Supplements Regulations 2003 that govern how an already-lawful supplement ingredient must be presented and formulated once it can legally be sold. A novel food determination answers whether an ingredient can be placed on the market at all; the Food Supplements Regulations and related labelling law then govern how a lawfully placed supplement is formulated, labelled and marketed.

Frequently asked questions

Q.Does an EU novel food authorisation automatically apply in Great Britain after Brexit?+

Not automatically for decisions made after the end of the transition period. GOV.UK's guidance on novel food consultation outcomes states that EU novel food status decisions made before 1 January 2021 still apply in GB by default, but EU decisions made after that date do not automatically apply in GB — the ingredient needs its own GB determination or authorisation under assimilated Regulation (EU) 2015/2283.

Q.What is the cut-off date for deciding whether a food is "novel" in the UK?+

15 May 1997. FSA and Food Standards Scotland guidance both define a novel food as one not used for human consumption to a significant degree in the UK or EU before that date — the date the original EU novel foods regulation took effect.

Q.Who authorises novel foods for the GB market — the FSA or Food Standards Scotland?+

Both are involved. The FSA covers England and Wales, Food Standards Scotland (FSS) covers Scotland, and the eventual authorisation decision is made by the relevant ministers in England, Wales and Scotland together, with the result reflected in the GB Register of novel foods that both agencies refer applicants and consumers to.

Q.Does a GB novel food authorisation cover Northern Ireland too?+

No. Northern Ireland continues to follow EU novel food law under the Windsor Framework arrangements rather than the GB assimilated-law regime, so a brand selling into Northern Ireland needs to check the EU novel food status of the ingredient (via EFSA and the EU Novel Food Catalogue) separately from its GB authorisation status.

Q.Are CBD extracts currently authorised as novel foods in Great Britain?+

At the point this article's sources were reviewed, the FSA's CBD guidance stated that CBD extracts and isolates were confirmed as novel foods in January 2019 and that no CBD extracts or isolates had yet been granted a full novel food authorisation, although a published FSA list tracked products linked to applications validated or progressing toward validation. Brands should check the FSA's current CBD guidance and linked-applications register directly, since both are updated over time.

Q.If my supplement uses a well-known plant, can I assume it is not a novel food?+

No. The FSA's own CBD guidance illustrates the opposite: hemp seed and certain hemp leaf infusions are treated as non-novel because that specific form has a documented consumption history, but CBD extracted from the same plant is treated as novel because the extract itself has no such history. The question is about the specific ingredient form being sold, not the source plant generally.

Primary sources

  • FSA — Novel foods authorisation guidance (food.gov.uk) — reviewed 9 Oct 2026
  • FSA — Cannabidiol (CBD) guidance (food.gov.uk) — reviewed 9 Oct 2026
  • FSA — CBD products linked to novel food applications (food.gov.uk) — reviewed 9 Oct 2026
  • Food Standards Scotland — Novel foods authorisation guidance — reviewed 9 Oct 2026
  • GOV.UK — Outcomes on novel food consultations (Northern Ireland position) — reviewed 9 Oct 2026
  • legislation.gov.uk — Regulation (EU) 2015/2283 on novel foods — reviewed 9 Oct 2026
  • legislation.gov.uk — The Novel Foods Regulations (Northern Ireland) 2017 — reviewed 9 Oct 2026

Further reading

  • UK Food Supplements Regulations 2003
    The compositional and labelling framework that applies once an ingredient is lawfully on the UK market — separate from the novel food question covered here.
  • Dietary Supplement Operations Guide
    Operational context for formulation, specification, and documentation decisions a brand makes once an ingredient's regulatory status is confirmed.
Talk to us about UK FSA Novel Food (Post-Brexit)

Want to see how UK FSA Novel Food (Post-Brexit) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Inside V5
  • → QMS — quality records next to the work they concern.
  • → Document control — one version in force, every change signed and explained.
  • → Score your compliance gap — then download the validation pack.
Regulatory anchors
  • Regulation (EU) 2015/2283 (retained)
Related terms
  • → UK Food Supplements (England) Regulations 2003

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC